Concerns about fertility kept a third of young women with breast cancer from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer coming back.
Diane Simeone, M.D., director of the Pancreatic Cancer Center at the University of Michigan, was recently named the upcoming chair of the National Scientific and Medical Advisory Board for the Pancreatic Cancer Action Network.
The University of Michigan Comprehensive Cancer Center’s Breast Oncology Program was one of nine beneficiaries of the 2014 QVC Presents "FFANY Shoes on Sale" event. FFANY and QVC representatives presented a check for $380,000 to the Cancer Center.
Andrew D. Rhim, M.D., assistant professor of gastroenterology, received a 2015 Clinical Scientist Development Award from the Doris Duke Charitable Foundation to advance research on pancreatic cancer.
Cancerous tumors cast off tiny telltale genetic molecules known as microRNAs and a team of University of Michigan researchers has come up with an efficient way to detect them in blood.
President Barack Obama announced his selection of Max S. Wicha, M.D., as one of five new appointees to the National Cancer Advisory Board.
A new study suggests that fusion of one normal cell with another — as observed in inflammation, infection, and injury from carcinogens — triggers a “genomic catastrophe” that converts normal cells to cancer cells and enables tumors to form.
Cancer Center researchers presented on care coordination and quality of care in colorectal cancer, imaging to predict sarcoma treatment, using serial biopsies to find aggressive prostate cancer, and side effects of oral chemotherapy at the American Society of Clinical Oncology annual meeting.
A survey of women with breast cancer found that nearly half considered having a double mastectomy. But of those who considered it, only 37 percent knew that the more aggressive procedure does not improve survival for women with breast cancer.
In a major advance in precision medicine, an international collaboration of researchers found 90 percent of castration resistant metastatic prostate cancers harbored some kind of genetic anomaly that could drive treatment choices.